GRN and non-small cell lung carcinoma: Notably, in February 2022, the first in-human phase 1 study of the anti-progranulin antibody AG01 [76] was started in patients with advanced solid tumors, particularly triple negative breast cancer, hormone-resistant breast cancer, NSCLC and mesothelioma patients (ClinicalTrials.gov Identifier: NCT05627960).